Dataset: Transcription profiling of mouse embryonic stem cell line E14TG2a with transient expression of T-Antigen
[u'This experiment is part of the FunGenES project (FunGenES - Functional Genomics in Embryonic Stem Cells partially funded by the 6th...
[u'This experiment is part of the FunGenES project (FunGenES - Functional Genomics in Embryonic Stem Cells partially funded by the 6th Framework Programme of the European Union, ', {u'a': {u'href': u'http://www.fungenes.org', u'target': u'_blank', u'$': u'http://www.fungenes.org'}}, u'). The experiment was conducted at the Dresden University of Technology (TUD), Germany. The purpose of the experiment was to identify changes in the expression profile of the cells caused by transient expression of T-Antigen can be reversed. Materials and methods: Induction: The cells are treated for 6 days with either Mibolerone and Doxycycline (for the ABD clone) or with Dexamethasone and Doxycycline (for the GBD* clone). Induction means that the T-Antigen is expressed. Deinduction: the cells are treated for 6 days with the above compounds and then cultured for another 6 days without the compounds. After deinduction the expression of T-Antigen stops. Untreated cells means that the cells were cultured for the period of 12 days without any compounds, there is no expression of T-Antigen. Relationships between samples: Two different E14TG2a lines (ABD and GBD) were made: both lines carry a construct containing the SV40 Large-T Antigen under the control of the tetracycline promoter. The ABD line also contains the reverse tet-repressor fused to VP16 and Androgen Binding Domain (ABD) under the control of the CAGGs promoter. The GBD*-clone carries a construct containing the reverse tet-repressor fused to VP16 and mutated Glucocorticoid Binding Domain (GBD*) under the control of the CAGGs promoter (GBD*-clone). Treatments: Cells are treated for 6 days with either Mibolerone and Doxycycline (for the ABD clone) or with Dexamethasone and Doxycycline (for the GBD* clone)']
- Species:
- mouse
- Samples:
- 18
- Source:
- E-TABM-675
- Updated:
- Dec.12, 2014
- Registered:
- Nov.21, 2014
Sample | StrainOrLine | Compound |
---|---|---|
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD06dyes06dnot_01 | E14TG2a_ABD | mibolerone and doxycycline |
TUD-1_an1_ABD12dnot_01 | E14TG2a_ABD | control |
TUD-1_an1_ABD12dnot_01 | E14TG2a_ABD | control |
TUD-1_an1_ABD12dnot_01 | E14TG2a_ABD | control |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD06dyes06dnot_01 | E14TG2a_GBD | dexamethasone and doxycycline |
TUD-1_an1_GBD12dnot_01 | E14TG2a_GBD | control |
TUD-1_an1_GBD12dnot_01 | E14TG2a_GBD | control |
TUD-1_an1_GBD12dnot_01 | E14TG2a_GBD | control |